for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aspen Pharmacare Holdings Limited

APNJ.J

Latest Trade

20,614.00ZAc

Change

64.00(+0.31%)

Volume

524,050

Today's Range

20,436.00

 - 

21,025.00

52 Week Range

13,555.00

 - 

28,167.00

As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
20,550.00
Open
20,875.00
Volume
524,050
3M AVG Volume
25.54
Today's High
21,025.00
Today's Low
20,436.00
52 Week High
28,167.00
52 Week Low
13,555.00
Shares Out (MIL)
455.16
Market Cap (MIL)
93,572.56
Forward P/E
13.06
Dividend (Yield %)
1.28

Next Event

Half Year 2022 Aspen Pharmacare Holdings Ltd Earnings Release

Latest Developments

More

S.Africa's Aspen Signs Term Sheet On Manufacture And Sale Of Aspen Branded COVID-19 Vaccine

Aspen Pharmacare Proposes Deal For Consideration Of About R1.8 Bln

Aspen Pharmacare FY HEPS From Contops 1,204.3 Cents

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both active pharmaceutical ingredients (APIs) and finished dose form. The Company is focused on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments: Manufacturing and Commercial Pharmaceuticals. The Manufacturing segment relates to the manufacture and sale of APIs and finished dose form products to third-party customers. Its Commercial Pharmaceuticals segment comprises Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products. It operates approximately 23 manufacturing facilities on six continents. Its manufacturing capabilities cover a wide variety of product-types, including orals, liquids, steriles, biologicals and APIs.

Industry

Biotechnology & Drugs

Contact Info

Aspen Place, 9 Rydall Vale Park

Douglas Saunders Drive ,La Lucia Ridge

South Africa

+27.11.2396100

http://www.aspenpharma.com/

Executive Leadership

Kuseni Douglas Dlamini

Independent Non-Executive Chairman of the Board

Stephen Bradley Saad

Group Chief Executive, Executive Director

Michael Guy Attridge

Deputy Group Chief Executive Officer, Finance Director, Executive Director

Sean Capazorio

Group Finance Officer, Executive Director

Richelle Crots

Regional Chief Executive Officer, SA Commercial

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, ZAR)

2019

38.9K

2020

38.6K

2021

37.8K

2022(E)

42.4K
EPS (ZAR)

2019

14.143

2020

12.680

2021

11.190

2022(E)

15.021
Price To Earnings (TTM)
19.50
Price To Sales (TTM)
2.48
Price To Book (MRQ)
1.42
Price To Cash Flow (TTM)
14.54
Total Debt To Equity (MRQ)
37.90
LT Debt To Equity (MRQ)
0.41
Return on Investment (TTM)
5.10
Return on Equity (TTM)
3.95

Latest News

Latest News

S.Africa's Aspen signs deal paving way for J&J COVID vaccine licence

South Africa's Aspen Pharmacare took a step towards a licensing deal to package and sell Johnson & Johnson's COVID-19 vaccine in Africa, announcing on Tuesday it had signed non-binding terms with subsidiaries of the U.S. drugmaker.

South Africa's Aspen in advanced talks over COVID-19 vaccine deal

Aspen Pharmacare is in advanced discussions over a potential licensing agreement to package the COVID-19 vaccine in South Africa, it said on Monday.

S.Africa's Aspen seeks licence for J&J COVID shot as EU shipments halted

Aspen Pharmacare said on Thursday it was in talks to make Johnson & Johnson's coronavirus shot under licence in South Africa, at what would be the continent's first major independent distribution base for a global vaccine against COVID-19.

Aspen eyes Serum Institute model as it seeks licence to make J&J vaccine

South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.

Facing backlash, EU says import of J&J vaccines from South Africa is temporary

The European Commission said on Thursday it had reached a temporary agreement with South Africa to use a plant there to bottle Johnson & Johnson COVID-19 vaccines that are being imported into the EU, after criticism of the arrangement.

Aspen to start J&J COVID-19 vaccine supplies to South Africa from Monday

South Africa's Aspen Pharmacare will supply the first batch of Johnson & Johnson COVID-19 vaccine to the country from July 26, the drugmaker said on Monday.

Aspen to partner with finance institutions to boost vaccine know-how

A group of global finance institutions led by the World Bank's International Finance Corporation (IFC) said on Wednesday they would help to facilitate an increase in vaccine manufacturing know-how in Africa by partnering with South African pharmaceutical company Aspen Pharmacare...

J&J to send 2 million COVID-19 vaccine doses to S.Africa by end-June -President Ramaphosa

South African President Cyril Ramaphosa said on Tuesday that Johnson & Johnson would send 2 million COVID-19 vaccine doses to the country by the end of the month, making up for the amount lost due to contamination at an U.S. ingredient supplier.

J&J to send S.Africa more than 300,000 vaccine doses, says Aspen

Johnson & Johnson (J&J) will export more ready-to-administer COVID-19 vaccines to South Africa beyond the 300,000 doses already pledged, the CEO of Aspen Pharmacare said on Monday.

J&J will export more COVID-19 vaccines to South Africa beyond 300,000 doses already promised - Aspen CEO

Johnson & Johnson will be exporting more ready-to-administer doses to the South African government beyond the 300,000 that was been announced by the local drug regulator on Sunday, CEO of Aspen Pharmacare said on Monday.

UPDATE 1-S.Africa's Aspen Pharmacare to supply J&J's COVID-19 vaccine by end-June

Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday.

UPDATE 1-South Africa's Aspen Pharmacare reports 18% drop in half-year profit

* Tech transfer for J&J COVID-19 vaccine by Q2 (Adds details of COVID-19 vaccine, numbers)

EU antitrust regulators accept Aspen offer to cut cancer, ends probe

EU antitrust regulators accepted on Wednesday South African pharmaceutical company Aspen's offer to cut the prices of six cancer drugs by 73% and to set a 10-year price cap in return for ending a three-year long investigation that could have resulted in a hefty fine.

Exclusive-Aspen to dodge EU antitrust fine with cancer drug price cut offer -sources

South African pharmaceutical company Aspen is set to avoid a potentially hefty EU antitrust fine, with regulators poised to accept its offer to cut cancer drug prices in the coming weeks, two people familiar with the matter said.

EXCLUSIVE-EU antitrust regulators set to accept Aspen concessions - sources

EU antitrust regulators are set to accept South African pharmaceutical company Aspen's concessions aimed at ending a three-year long investigation that could lead to a hefty fine, two people familiar with the matter said. Aspen last year offered to cut prices by an average...

South Africa's Aspen agrees initial deal to make J&J vaccine candidate

South African pharmaceutical company Aspen Pharmacare <APNJ.J> said on Monday it had reached a preliminary agreement with Johnson & Johnson <JNJ.N> to commercially manufacture its COVID-19 vaccine candidate, sending its shares higher.

South Africa's Aspen to seek acquisitions in emerging markets

South African pharmaceutical major Aspen Pharmacare Holdings Ltd said on Thursday it is planning to expand its portfolio in emerging markets through a mix of organic growth and acquisitions, as part of a new strategy.

UPDATE 1-S.Africa's Aspen sells thrombosis drug business to Mylan, shares jump

South African drugmaker Aspen Pharmacare has agreed to sell the rights to its European thrombosis business to U.S. pharmaceutical company Mylan for almost 642 million euros ($759 million), sending its shares up 7% on Tuesday.

Aspen offers to cut cancer drug prices, may avoid EU antitrust fine

Aspen <APNJ.J> has offered to cut prices by an average of 73% for six off-patent cancer drugs, EU antitrust regulators said on Tuesday, a move that could help the South African pharmaceutical company avoid a potentially hefty fine.

BRIEF-UK's CMA Says Aspen, Tiofarma, Amilco Admit Taking Part In Anti-Competitive Agreement

* CMA LEVIES FINES OF £2.3M AND SECURES £8M FOR NHS IN PHARMA PROBE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up